Changes in Lipoprotein‐Associated Phospholipase A2 Activity Predict Coronary Events and Partly Account for the Treatment Effect of Pravastatin: Results From the Long‐term Intervention with Pravastatin in Ischemic Disease Study-Reference-Cited by-同舟云学术

Changes in Lipoprotein‐Associated Phospholipase A2 Activity Predict Coronary Events and Partly Account for the Treatment Effect of Pravastatin: Results From the Long‐term Intervention with Pravastatin in Ischemic Disease Study

Published:2013-09-26 Issue:5 Volume:2 Page:
ISSN:2047-9980
Container-title:Journal of the American Heart Association
language:en
Short-container-title:JAHA

Author:

White Harvey D.¹,Simes John²,Stewart Ralph A. H.¹,Blankenberg Stefan³,Barnes Elizabeth H.²,Marschner Ian C.²⁴,Thompson Peter⁵,West Malcolm⁶,Zeller Tanja³,Colquhoun David M.⁷,Nestel Paul⁸,Keech Anthony C.²,Sullivan David R.⁹,Hunt David¹⁰,Tonkin Andrew¹¹,

Affiliation:

1. Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand

2. NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia

3. University Heart Centre Hamburg, Hamburg, Germany

4. Department of Statistics, Macquarie University, Sydney, Australia

5. University of Western Australia, Perth, Australia

6. University of Queensland, Brisbane, Australia

7. Greenslopes Hospital, Greenslopes, Australia

8. Baker IDI Heart and Diabetes Institute, Melbourne, Australia

9. Royal Prince Alfred Hospital, Camperdown, Australia

10. Department of Cardiology and University of Melbourne, Melbourne, Australia

11. Monash University, Melbourne, Australia